Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jessica M. Lawton"'
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(7)
Introduction Pemigatinib is an FGFR inhibitor that is one of few second-line treatment options for cholangiocarcinoma. Nail toxicities were common in the phase 2 study evaluating the safety and efficacy of pemigatinib. Case report We describe a 54-ye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31d2ca44a26341dd759551f0fa2fafe7
https://pubmed.ncbi.nlm.nih.gov/33736556
https://pubmed.ncbi.nlm.nih.gov/33736556
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(4)
Introduction Atezolizumab is currently the only immunotherapy used in conjunction with nab-paclitaxel for locally advanced or triple negative breast cancer. Limited data is available regarding hemolytic anemia as a side effect of atezolizumab. Case r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22aa03246758a48e6cb4fa608d239c05
https://pubmed.ncbi.nlm.nih.gov/32951522
https://pubmed.ncbi.nlm.nih.gov/32951522
Autor:
Abigail Harper, Wendy Hui, Jessica M. Lawton, George W. Carro, Pamela Menas, Douglas E. Merkel
Publikováno v:
Journal of Oncology Pharmacy Practice. 18:387-393
Purpose:Aromatase inhibitors (AIs) are routinely used as first-line adjuvant treatment of breast cancer in postmenopausal women with hormone receptor positive tumors. The current recommended length of treatment with an AI is 5 years. Arthralgias have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e96c22a4799d7f36ca9f01008a22b2e0
https://doi.org/10.1177/1078155211434853
https://doi.org/10.1177/1078155211434853
Autor:
Wayne Spath, Abigail Harper, Cara A. Harshberger, Bruce Brockstein, Jessica M. Lawton, Wendy Hui, George W. Carro
Computerized physician order entry (CPOE) in electronic health records (EHR) has been recognized as an important tool in optimal health care provision that can reduce errors and improve safety. The objective of this study is to describe documentation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e6554f3bff79c00363dcd1874e95f6a
https://europepmc.org/articles/PMC3140445/
https://europepmc.org/articles/PMC3140445/
Autor:
Jessica M. Lawton, A. Blankenship, Douglas E. Merkel, P. Menas, Abigail Harper, Wendy Hui, George W. Carro
Publikováno v:
Journal of Clinical Oncology. 28:e11062-e11062
e11062 Background: Aromatase inhibitors (AIs) are often used as first-line adjuvant treatment of breast cancer in postmenopausal women with hormone receptor positive tumors. Recommended length of A...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::186d03e8c356a7ea7b08f28c87c989e0
https://doi.org/10.1200/jco.2010.28.15_suppl.e11062
https://doi.org/10.1200/jco.2010.28.15_suppl.e11062
Publikováno v:
Journal of Clinical Oncology. 27:e20677-e20677
e20677 Background: Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor is utilized to treat a wide range of cancers. However, clinical trials of bevacizumab reported the incidence of hypertension (HTN) up to 36%. A national guideline h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21bb9086962f0149aa0edf834472de7f
https://doi.org/10.1200/jco.2009.27.15_suppl.e20677
https://doi.org/10.1200/jco.2009.27.15_suppl.e20677
Publikováno v:
Journal of Clinical Oncology. 25:17058-17058
17058 Background: Computerized physician order entry (CPOE) in electronic medical records (EMR) has been recognized as an important tool in optimal health care provision that can reduce errors and improve safety. The objective of this study is to des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b30f3697a0d7306bb5e734bef7c1915
https://doi.org/10.1200/jco.2007.25.18_suppl.17058
https://doi.org/10.1200/jco.2007.25.18_suppl.17058
Publikováno v:
Blood. 108:4851-4851
Twenty two patients (pts) with primary or therapy-related MDS were treated with 5-azayctidine (AZA) at the Kellogg Cancer Care Centers (KCCC) from July 2004–May 2006. We retrospectively reviewed all consecutive patients with myelodysplastic syndrom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba4996b20f94f4f5ee96538713cc6af6
https://doi.org/10.1182/blood.v108.11.4851.4851
https://doi.org/10.1182/blood.v108.11.4851.4851
Autor:
George W. Carro, Seema Bavisi, David L. Grinblatt, L. Kaminer, William J. Uhlig, Jessica M. Lawton
Publikováno v:
Blood. 108:4691-4691
Maintaining dose intensity in Hodgkin’s Lymphoma (HL) correlates with an improved outcome in patients treated with combination chemotherapy. Filgrastim is commonly used as secondary prophylaxis for neutropenia to avoid dose delays and dose reductio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1bde28984937585f4080b53e3ac7adb
https://doi.org/10.1182/blood.v108.11.4691.4691
https://doi.org/10.1182/blood.v108.11.4691.4691